Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. QIAGEN N.V.
  6. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
47.42(c) 47.69(c) 48.03(c) 46.77(c) 47.12(c) Last
724 936 558 074 611 416 993 721 837 483 Volume
-0.94% +0.57% +0.71% -2.62% +0.75% Change
More quotes
Financials (USD)
Sales 2021 2 265 M - -
Net income 2021 492 M - -
Net Debt 2021 887 M - -
P/E ratio 2021 21,8x
Yield 2021 -
Sales 2022 2 198 M - -
Net income 2022 455 M - -
Net Debt 2022 453 M - -
P/E ratio 2022 23,9x
Yield 2022 -
Capitalization 10 763 M 10 763 M -
EV / Sales 2021 5,14x
EV / Sales 2022 5,10x
Nbr of Employees 5 750
Free-Float 98,2%
More Financials
Company
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or... 
Sector
Biotechnology & Medical Research
Calendar
06/29 | 09:00amShareholder meeting
More about the company
Ratings of QIAGEN N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about QIAGEN N.V.
06/17QIAGEN NV  : Deutsche Bank reiterates its Buy rating
MD
06/15QIAGEN N  : Shareholder Davidson Kempner European Partners To Vote Against Chair..
MT
06/11QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/11DGAP-PVR  : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG ..
DJ
06/11Today on Wall Street: Much ado about nothing
06/11ANALYST RECOMMENDATIONS : Brown-Forman, Casey's General Stores, GameStop, Reckit..
06/11QIAGEN NV  : Berenberg reaffirms its Buy rating
MD
06/09ANALYST RECOMMENDATIONS : APA, Bank of America, Citigroup, Goldman Sachs, Visa....
06/08QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/08DGAP-PVR : QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [..
DJ
06/08QIAGEN NV  : Goldman Sachs gives a Buy rating
MD
06/07PRESS RELEASE : Innovative Molecules raises EUR20 million Series A equity financ..
DJ
06/03QIAGEN N  : Goldman Sachs Starts Qiagen NV at Neutral With $52 Price Target
MT
06/03QIAGEN NV  : Goldman Sachs remains Neutral
MD
06/03QIAGEN NV  : Gets a Neutral rating from Jefferies
MD
More news
News in other languages on QIAGEN N.V.
06/18WOCHENVORSCHAU : Termine bis 02. Juli 2021
06/18WOCHENVORSCHAU : Termine bis 01. Juli 2021
06/17WOCHENVORSCHAU : Termine bis 30. Juni 2021
06/16MORNING BRIEFING - Deutschland/Europa -2-
06/16WOCHENVORSCHAU : Termine bis 29. Juni 2021
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Chart QIAGEN N.V.
Duration : Period :
QIAGEN N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 57,46 $
Last Close Price 47,12 $
Spread / Highest target 52,8%
Spread / Average Target 21,9%
Spread / Lowest Target -13,0%
EPS Revisions
Managers and Directors
NameTitle
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.-10.84%10 763
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367